Wilson Sonsini Advises Bolt Medical on Merger with Boston Scientific

Client Highlights

January 13, 2025

On January 8, 2025, Boston Scientific announced it has entered into a definitive agreement to acquire Bolt Medical, the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for the treatment of coronary and peripheral artery disease, for up to $900 million. Wilson Sonsini Goodrich & Rosati advised Bolt Medical on the transaction.

Boston Scientific initially developed the concept for the Bolt IVL system and helped establish Bolt Medical in 2019 and currently holds approximately 26 percent equity in the company. On a 100 percent basis before consideration of Boston Scientific's current equity ownership in Bolt Medical, debt, and other closing adjustments, the transaction price consists of $600 million up front, and up to $300 million upon achievement of certain regulatory milestones. As a result, the transaction consists of an upfront payment of approximately $443 million for the 74 percent stake not yet owned and up to $221 million upon achievement of certain regulatory milestones. The transaction is expected to be completed in the first half of 2025, subject to customary closing conditions.

The Wilson Sonsini team that advised Bolt Medical on the transaction includes:

M&A/Corporate
Rob Ishii
Scott Murano
Catherine Riley Tzipori
David Adler
Daniel Cho
Dani Glazer Signaigo
Robert Gunn
Alan Jiang